Exact Sciences Corp
—- Market cap
- —
- Debt
- +$2.85B
- Cash
- −$964.71M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXAS stock price vs SBRA: inconclusive — current versus $116.57 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SBRA's multiple
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXAS FY 2025 (ended Dec 31, 2025) · SBRA FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 68% equity / 32% debt · EV / Revenue 10.03x · EV / EBITDA 27.01x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
SABRA HEALTH CARE REIT, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.19x
0.90x
Net debt / EBITDA
Leverage against operating earnings
35.68x
8.55x
Cash and equivalents
Liquid reserves on the balance sheet
$964.71M
$71.54M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
WELLTOWER INC.
EXAS vs WELL
MEDICAL PROPERTIES TRUST INC
EXAS vs MPW
ALEXANDRIA REAL ESTATE EQUITIES, INC.
EXAS vs ARE
NATIONAL HEALTH INVESTORS INC
EXAS vs NHI
$2.85B
$2.53B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.